ישראל - עברית - Ministry of Health

neopharm ltd - fentanyl as citrate 100 mcg - tablets sublingual - fentanyl - management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.

ישראל - עברית - Ministry of Health

neopharm ltd - fentanyl as citrate 200 mcg - tablets sublingual - fentanyl - management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.

ישראל - עברית - Ministry of Health

neopharm ltd - fentanyl as citrate 300 mcg - tablets sublingual - fentanyl - management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.

ישראל - עברית - Ministry of Health

neopharm ltd - fentanyl as citrate 400 mcg - tablets sublingual - fentanyl - management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.

ישראל - עברית - Ministry of Health

neopharm ltd - fentanyl as citrate 600 mcg - tablets sublingual - fentanyl - management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.

ישראל - עברית - Ministry of Health

neopharm ltd - fentanyl as citrate 800 mcg - tablets sublingual - fentanyl - management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.

ישראל - עברית - Ministry of Health

rafa laboratories ltd - buprenorphine as hydrochloride 2 mg - tablets sublingual - buprenorphine - substitution treatment for opioid dependence within a framework of medical, social and psychological treatment.

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 100 u/vial - botulinum toxin - botulinum toxin - botox is indicated for the symptomatic relief of blepharospasm or vii nerve disorders in patients over 12 years hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. botox is also indicated for the reduction of the signs and symptoms of spasmodic torticollis ( cervical dystonia) in adults. botox is also indicated for the treatment of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy patients two years of age or older. focal upper limb spasticity associated with stroke. botox is indicated also for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients aged 65 years or less. management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment.symptom relief in adults fulfilling criteria for chronic migraine (headaches on ?15 days per month of which at least 8 days with migrai

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 50 u/vial - botulinum toxin - botulinum toxin - botox is indicated for the symptomatic relief of blepharospasm or vii nerve disorders in patients over 12 years hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. botox is also indicated for the reduction of the signs and symptoms of spasmodic torticollis ( cervical dystonia) in adults. botox is also indicated for the treatment of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy patients two years of age or older. focal upper limb spasticity associated with stroke. botox is indicated also for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients aged 65 years or less. management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment.symptom relief in adults fulfilling criteria for chronic migraine (headaches on ?15 days per month of which at least 8 days with migrai

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 200 u/vial - botulinum toxin - botulinum toxin - botox is indicated for the symptomatic relief of blepharospasm or vii nerve disorders in patients over 12 years hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. botox is also indicated for the reduction of the signs and symptoms of spasmodic torticollis ( cervical dystonia) in adults. botox is also indicated for the treatment of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy patients two years of age or older. focal upper limb spasticity associated with stroke. botox is indicated also for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients aged 65 years or less.management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment.symptom relief in adults fulfilling criteria for chronic migraine (headaches on ?15 days per month of which at least 8 days with migrain